Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00173901 |
The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.
Condition | Intervention | Phase |
---|---|---|
Infection |
Drug: ceftazidime |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety Study |
Official Title: | Adverse Drug Reactions of Different Brands of Ceftazidime Injection |
Estimated Enrollment: | 536 |
Study Start Date: | March 2001 |
Estimated Study Completion Date: | April 2002 |
Ceftazidime is a third generation cephalosporins that should be reserved for severe bacterial infections. Substitution of the brand ceftazidime with a generic ceftazidime raised some concerns. The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.
Ages Eligible for Study: | 1 Year to 95 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Taiwan | |
National Taiwan University Hospital | |
Taipei, Taiwan, 100 |
Study Chair: | Shan-Chwen Chang, MD PhD | National Taiwan University Hospital |
Study ID Numbers: | 900104 |
Study First Received: | September 12, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00173901 History of Changes |
Health Authority: | Taiwan: Department of Health |
ceftazidime safety infection |
Ceftazidime Anti-Bacterial Agents Drug Toxicity Poisoning Disorders of Environmental Origin |
Ceftazidime Anti-Infective Agents Anti-Bacterial Agents Drug Toxicity Therapeutic Uses |
Poisoning Disorders of Environmental Origin Infection Pharmacologic Actions |